BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28176892)

  • 1. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.
    Donohue JF; Betts KA; Du EX; Altman P; Goyal P; Keininger DL; Gruenberger JB; Signorovitch JE
    Int J Chron Obstruct Pulmon Dis; 2017; 12():367-381. PubMed ID: 28176892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
    Roskell NS; Anzueto A; Hamilton A; Disse B; Becker K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():813-24. PubMed ID: 25114521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.
    Schlueter M; Gonzalez-Rojas N; Baldwin M; Groenke L; Voss F; Reason T
    Ther Adv Respir Dis; 2016 Apr; 10(2):89-104. PubMed ID: 26746383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
    Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
    Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
    Koch A; Pizzichini E; Hamilton A; Hart L; Korducki L; De Salvo MC; Paggiaro P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
    Vogelmeier C; Zhong N; Humphries MJ; Mezzi K; Fogel R; Bader G; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3189-3197. PubMed ID: 28008244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis.
    Aziz MIA; Tan LE; Wu DB; Pearce F; Chua GSW; Lin L; Tan PT; Ng K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3203-3231. PubMed ID: 30349228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
    Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
    Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
    Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
    Cope S; Zhang J; Williams J; Jansen JP
    BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM; Liang ZA; Zheng QL; Wang RC; Luo J; Li CT
    Lung; 2013 Apr; 191(2):135-46. PubMed ID: 23306410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
    Ismaila AS; Huisman EL; Punekar YS; Karabis A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2495-517. PubMed ID: 26604738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
    Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E; Brusselle GG; Joos GF
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.